TREZIX

Post-LOE

acetaminophen; caffeine; dihydrocodeine bitartrate

Passkey Therapeutics

ANDAORALCAPSULE

Approved

Nov 2014

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

4/8 — Partial

TREZIX (acetaminophen; caffeine; dihydrocodeine bitartrate) by Passkey Therapeutics is clinical pharmacology: trezix™ capsules contain dihydrocodeine which is a semi-synthetic narcotic analgesic related to codeine, with multiple actions qualitatively similar to those of codeine; the most prominent of these involve the central nervous system and organs with smooth muscle components. Approved for minor aches, pains due to: headache sore throat flu toothache the common cold temporarily reduces fever. First approved in 2014.

Drug data last refreshed 19h ago

$0.0BPart D

Mechanism of Action

CLINICAL PHARMACOLOGY: TREZIX™ capsules contain dihydrocodeine which is a semi-synthetic narcotic analgesic related to codeine, with multiple actions qualitatively similar to those of codeine; the most prominent of these involve the central nervous system and organs with smooth muscle components.…

Indications (2)

minor aches pains due to: headache sore throat flu toothache the common cold temporarily reduces fever

Worked on TREZIX at Passkey Therapeutics? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.